title: Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes.
abstract: The present paper addresses the question how alpha-glucosidase inhibitors affect glucose homeostasis. To facilitate this already established data on the effects of induced malabsorption on gut hormones such as gastric inhibitory polypeptide (GIP) in connection with preliminary findings which deal with the new incretin hormone glucagon-like peptide 1 (7-36) amide (GLP-1) are discussed. To emphasize the possibly important impact of a regulated GLP-1 release in response to glucosidase inhibitor treatment we evaluate the recently introduced concept of 'glucose competence' of pancreatic beta-cells. The slowing of nutrient (i.e. glucose) absorption by therapeutic means (for example, acarbose) could supplement a new approach in the treatment of type 2 diabetics which would utilize the well-preserved insulinotropic activity of GLP-1 in these patients, its glucagon-lowering effect, and its possible inhibition of gastric emptying rates, the latter helping to reduce the requirement for rapid insulin secretory responses as is intended while using alpha-glucosidase inhibitor treatment.
authors.affiliation: Department of Internal Medicine, Philipps University, Marburg, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Göke
authors.forename: C
authors.initials: C
authors.lastname: Herrmann
authors.forename: R
authors.initials: R
authors.lastname: Göke
authors.forename: H C
authors.initials: HC
authors.lastname: Fehmann
authors.forename: P
authors.initials: P
authors.lastname: Berghöfer
authors.forename: G
authors.initials: G
authors.lastname: Richter
authors.forename: R
authors.initials: R
authors.lastname: Arnold
mesh_terms: D000818:Animals; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D004040:Dietary Carbohydrates; D005749:Gastric Inhibitory Polypeptide / Q000378:metabolism; D005768:Gastrointestinal Hormones / Q000378:metabolism*; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000378:metabolism*; D065089:Glycoside Hydrolase Inhibitors; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007408:Intestinal Absorption / Q000187:drug effects*; D008954:Models, Biological; D010455:Peptides / Q000378:metabolism
chemical_list: D004040:Dietary Carbohydrates; D005768:Gastrointestinal Hormones; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D010455:Peptides; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005947:Glucose